An observational study in Peripheral Artery Disease and Heart Failure, sponsored by Tartu University Hospital. Recruiting at 1 site in Estonia. Open to participants aged 35 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-12-16.
Sponsored by Tartu University Hospital · Observational
Single centre observational study to assess lower extremity arterial disease (LEAD) patients' cardiac dysfunction with strain analyses and to assess connections between cardiac dysfunction, metabolomic changes and target organ damage in LEAD.
1,542 studies on the registry are indexed under Peripheral Arterial Disease; 282 are open to participants now.
This study's planned enrollment of 162 is below the median of 190 across 410 observational studies indexed under Peripheral Arterial Disease.
Browse Peripheral Arterial Disease studies →Tartu University Hospital is the lead sponsor of 24 studies on the registry; 10 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with cardiovascular risk factors
Inclusion Criteria in LEAD group:
Inclusion Criteria in control group:
Exclusion Criteria:
LEAD diagnosis confirmed by by ankle-brachial index (≤0,9 or \>1,3) or angiography. Fontaine I-IV class symptoms.
Matched with LEAD group's patients as much as possible for age, sex, smoking history, hypertension, diabetes, coronary artery disease.
left ventricular global longitudinal strain (GLS)
assessed by deformation analysis with echocardiography
Time frame: after enrollment and one year later
other echocardiographic parameters
left ventricular ejection fraction, left atrial strain, lateral, medial and averaged E/E', left atrial volume, maximal tricuspid regurgitation velocity, right ventricular strain
Time frame: after enrollment and one year later
heart failure diagnosis
according to European Society of Cardiology year 2021 heart failure guideline (i.e assessment of symptoms, ECG, natriuretic peptides)
Time frame: after enrollment and if necessary, reassessment one year later
arterial stiffness
peripheral/central blood pressure, augmentation index, pulse wave velocity in aorta
Time frame: after enrollment and one year later
cardiac- and renal injury markers
high-sensitivoty troponin T, natriuretic peptides (NT-proBNP), cystatine C, creatinine, urea, calculated eGFR
Time frame: after enrollment and one year later
metabolomics
low molecular weight metabolites
Time frame: after enrollment and one year later
markers of oxidative stress
oxidated LDL, interleukine-18, myeloperoxidase, isoprostanes
Time frame: after enrollment and one year later
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tartu University Hospital